Recent News

• 09.12.2025 - Nutriband Publishes Q2 Report and Announces Key FDA Meeting for AVERSA™ Fentanyl
• 09.10.2025 - Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
• 09.04.2025 - Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000
• 08.21.2025 - Nutriband Inc. Presented at the Emerging Growth Conference
• 08.11.2025 - Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election
• 08.08.2025 - FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
• 07.02.2025 - Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval
• 07.02.2025 - Nutriband Inc. added to the Russell Microcap® Index, Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index
• 06.18.2025 - Nutriband and Kindeva Complete Manufacturing Scale-Up for AVERSA™ Fentanyl
• 06.09.2025 - Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology

Recent Filings

• 09.09.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 09.03.2025 - 8-K Current report
• 08.07.2025 - 8-K Current report
• 07.16.2025 - 8-K Current report
• 07.08.2025 - 424B4 Prospectus [Rule 424(b)(4)]
• 07.03.2025 - POS AM Post-Effective amendments for registration statement
• 07.03.2025 - EFFECT Notice of Effectiveness
• 06.23.2025 - POS AM Post-Effective amendments for registration statement